Holen Sie sich die Stockscreener-App
11.05
6.97%
0.72
Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Nigeria
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - GlobeNewswire
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma - marketscreener.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board - TradingView
Eikon Therapeutics adds Merck chemistry head to advisory board - Investing.com
Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory Board - marketscreener.com
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th - marketbeat.com
Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial - Moomoo
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Eikon Therapeutics doses first patient in lung cancer trial - Investing.com
Eikon Therapeutics Doses First Patient in Phase 2/3 Trial for EIK1001 in Non-Small Cell Lung Cancer - marketscreener.com
Eikon Therapeutics doses first patient in lung cancer trial By Investing.com - Investing.com Canada
Eikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC - Quiver Quantitative
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer - GlobeNewswire
Eikon Therapeutics Ord Shs (EIKN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday - Sahm
Eikon Therapeutics Ord Shs (EIKN) Institutional Confidence - TradingKey
Eikon Therapeutics, Inc. Revenue Breakdown – BX:EIKN - TradingView
Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN) - Seeking Alpha
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress - The Manila Times
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European ... - Caledonian Record
Seven Eikon abstracts include lung and prostate cancer studies at ESMO - Stock Titan
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates? - Yahoo Finance
Eikon Therapeutics (EIKN) Surges Over 11% as Bullish Momentum BuildsAccumulation Line - dars.gov.et
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Growth Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Growth Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell Microcap Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Index - marketscreener.com
Eikon Therapeutics Jumps 16.24%: Key Levels and What Lies Ahead for EIKNRounding Top - po-news-eg.net
Eikon Therapeutics to join Russell 3000 index - MSN
Eikon Therapeutics to Join the Russell 3000 Index - marketscreener.com
Enterprise value to EBITDA forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics เตรียมเข้าคำนวณในดัชนี Russell 3000 หลังการปรับโครงสร้างดัชนีประจำปี - Moomoo
Price to sales forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Actuals & Estimates (NASDAQ:EIKN) - TradingView
Price to book forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics to join Russell 3000 Index on Friday By Investing.com - Investing.com South Africa
Price to earnings forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Enterprise value to EBIT forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Price to book forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Price to sales forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Eikon Therapeutics to join Russell 3000 Index on Friday - Investing.com
Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution - Quiver Quantitative
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):